Table 3 Univariate Cox proportional hazards regression for progression-free survival (PFS) and overall survival (OS)

From: Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

 

Patients

PFS

OS

Marker

n

%

HR

95% CI

P

HR

95% CI

P

TP53 mutation

 Absent

72

63

1.00

  

1.00

  

 Present

43

37

0.85

0.58–1.26

0.4

0.88

0.56–1.37

0.6

Kras mutation

 Absent

80

68

1.00

  

1.00

  

 Present

37

32

0.91

0.60–1.36

0.6

0.76

0.48–1.21

0.2

MSI

 Absent

114

98

1.00

  

1.00

  

 Present

2

2

0.36

0.05–2.62

0.3

0.40

0.06–2.92

0.4

MTHFR 677

 CC

43

37

1.00

  

1.00

  

 CT

54

47

0.81

0.53–1.24

0.3

1.10

0.68–1.76

0.7

 TT

19

16

1.05

0.61–1.81

0.9

1.35

0.75–2.45

0.3

 CT and TT

73

63

0.87

0.59–1.29

0.5

1.16

0.75–1.81

0.5

ERCC1-118

 CC

10

9

1.00

  

1.00

  

 CT

64

56

2.68

1.15–6.23

0.02

1.88

0.75–4.71

0.2

 TT

41

35

2.54

1.07–6.04

0.04

1.55

0.60–4.00

0.4

 CT and TT

105

91

2.62

1.14–6.02

0.02

1.74

0.70–4.30

0.2

XRCC1-399

 GG

39

34

1.00

  

1.00

  

 AG

61

53

0.57

0.28–1.19

0.1

0.92

0.58–1.45

0.7

 AA

15

13

1.01

0.39–2.60

1.0

0.52

0.24–1.14

0.1

 AG and AA

76

66

0.66

0.34–1.28

0.2

0.83

0.53–1.29

0.4

Back to article page